OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Rating of “Moderate Buy” from Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $13.4286.

OPRX has been the subject of a number of analyst reports. Wall Street Zen cut shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. Lake Street Capital cut their price target on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Weiss Ratings cut shares of OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, May 14th. Stephens cut their price target on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 13th. Finally, Stifel Nicolaus cut their price target on shares of OptimizeRx from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CenterBook Partners LP bought a new position in shares of OptimizeRx in the third quarter valued at approximately $6,331,000. Next Century Growth Investors LLC raised its stake in shares of OptimizeRx by 139.8% in the fourth quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock valued at $6,196,000 after acquiring an additional 294,688 shares during the last quarter. Wesbanco Bank Inc. bought a new position in shares of OptimizeRx in the third quarter valued at approximately $205,000. P.A.W. Capital Corp raised its stake in shares of OptimizeRx by 10.0% in the fourth quarter. P.A.W. Capital Corp now owns 55,000 shares of the company’s stock valued at $674,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Hillsdale Investment Management Inc. raised its stake in shares of OptimizeRx by 10.9% in the fourth quarter. Hillsdale Investment Management Inc. now owns 20,300 shares of the company’s stock valued at $249,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Stock Down 2.0%

OPRX stock opened at $4.98 on Friday. OptimizeRx has a twelve month low of $4.57 and a twelve month high of $22.25. The company has a market cap of $93.42 million, a PE ratio of 14.23 and a beta of 1.13. The business’s 50-day simple moving average is $5.72 and its 200 day simple moving average is $8.64. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%.The business had revenue of $19.84 million for the quarter, compared to the consensus estimate of $18.74 million. On average, research analysts anticipate that OptimizeRx will post 0.51 earnings per share for the current year.

OptimizeRx declared that its Board of Directors has approved a share repurchase program on Thursday, March 5th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.